Methodology

All entries for: MeiraGTx UK II Ltd

February 11, 2026

MeiraGTx UK II Ltd

Orphan Drug Designation

treatment of inherited retinal dystrophy due to GUCY2D gene mutations

Disease Area: Rare Disease
Source
Scroll to Top